Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Objective: (1) This study aims to identify distinct serum metabolites in gastric cancer patients compared to healthy individuals, providing valuable insights into postoperative efficacy evaluation and monitoring of gastric cancer recurrence; (2) Methods: Serum samples were collected from 15 healthy individuals, 16 gastric cancer patients before surgery, 3 months after surgery, 6 months after surgery, and 15 gastric cancer recurrence patients. T-test and analysis of variance (ANOVA) were performed to screen 489 differential metabolites between the preoperative group and the healthy control group. Based on the level of the above metabolites in the recurrence, preoperative, three-month postoperative, and six-month postoperative groups, we further selected 18 significant differential metabolites by ANOVA and partial least squares discriminant analysis (PLS-DA). The result of hierarchical clustering analysis about the above metabolites showed that the samples were regrouped into the tumor-bearing group (comprising the original recurrence and preoperative groups) and the tumor-free group (comprising the original three-month postoperative and six-month postoperative groups). Based on the results of PLS-DA, 7 differential metabolites (VIP > 1.0) were further selected to distinguish the tumor-bearing group and the tumor-free group. Finally, the results of hierarchical clustering analysis showed that these 7 metabolites could well identify gastric cancer recurrence; (3) Results: Lysophosphatidic acids, triglycerides, lysine, and sphingosine-1-phosphate were significantly elevated in the three-month postoperative, six-month postoperative, and healthy control groups, compared to the preoperative and recurrence groups. Conversely, phosphatidylcholine, oxidized ceramide, and phosphatidylglycerol were significantly reduced in the three-month postoperative, six-month postoperative, and healthy control groups compared to the preoperative and recurrence groups. However, these substances did not show significant differences between the preoperative and recurrence groups, nor between the three-month postoperative, six-month postoperative, and healthy control groups; (4) Conclusions: Our findings demonstrate the presence of distinct metabolites in the serum of gastric cancer patients compared to healthy individuals. Lysophosphatidic acid, triglycerides, lysine, sphingosine-1-phosphate, phosphatidylcholine, oxidized ceramide, and phosphatidylglycerol hold potential as biomarkers for evaluating postoperative efficacy and monitoring recurrence in gastric cancer patients. These metabolites exhibit varying concentrations across different sample categories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Particularly, lysophosphatidic acids, triglycerides, lysine, and sphingosine-1-phosphate revealed increased levels in the postoperative groups compared with the preoperative and recurrence groups.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“Meanwhile, phosphatidylcholine, oxidized ceramide, and phosphatidylglycerol displayed decreased levels.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“These results may suggest that these differential metabolites may be useful biomarkers for validating the prognosis and monitoring the recurrence of GC.”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, a study examining differential serum metabolites showed significant alterations in the abundance of several metabolites among patients before and after surgery [61].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
de Martel, C., Georges, D., Bray, F., Ferlay, J., & Clifford, G. M. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30488-7 · Cited by 2,475
Thrift, A. P., & El-Serag, H. B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.045 · Cited by 1,456
Gunderson, L. L., & Sosin, H. (1982) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(82)90377-7 · Cited by 488
Patterns of failure following curative resection of gastric carcinoma
Landry, J., Tepper, J. E., Wood, W. C., Moulton, E. O., Koerner, F., & Sullinger, J. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90344-j · Cited by 262
Gastric Cancer: Where Are We Heading?
Petryszyn, P., Chapelle, N., & Matysiak-Budnik, T. (2020) · Digestive Diseases · doi:10.1159/000506509 · Cited by 198
Ceramides as Novel Disease Biomarkers
Kurz, J., Parnham, M. J., Geisslinger, G., & Schiffmann, S. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.10.009 · Cited by 188
Kumar, A., & Deep, G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.03.017 · Cited by 185
Gastric cancer—Patterns of relapse after surgical resection
GUNDERSON, L. (2002) · Seminars in Radiation Oncology · doi:10.1053/srao.2002.30817 · Cited by 176
Burden of non-communicable diseases from infectious causes in 2017: a modelling study
Coates, M. M., Kintu, A., Gupta, N., Wroe, E. B., Adler, A. J., Kwan, G. F., Park, P. H., Rajbhandari, R., Byrne, A. L., Casey, D. C., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30358-2 · Cited by 155
Cited by
Matsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“Interestingly, a study examining differential serum metabolites showed significant alterations in the abundance of several metabolites among patients before and after surgery [61].”
BackgroundFan, S., Wang, W., Che, W., Xu, Y., Jin, C., Dong, L., & Xia, Q. (2025) · Metabolites · doi:10.3390/metabo15030201 · Cited by 50
Beyond Biomarkers: Machine Learning-Driven Multiomics for Personalized Medicine in Gastric Cancer
Ma, D., Fan, C., Sano, T., Kawabata, K., Nishikubo, H., Imanishi, D., Sakuma, T., Maruo, K., Yamamoto, Y., Matsuoka, T., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050166 · Cited by 34
Daliri, A., Roudposhti, K. K., Alimoradi, M., Sheikhha, M., Saraei, M. R. S., & Mohammadzadeh, J. (2025) · doi:10.1109/ipria68579.2025.11263556 · Cited by 5
Zhang, H., Shen, W.-B., & Chen, L. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i6.2419 · Cited by 2
Metadata
- Authors
- Qu, T., Zhang, S., Yang, S., Li, S., & Wang, D.
- Affiliations
- First Hospital of Jilin University (CN)
- Corresponding author
- Wang, Daguang
- Venue
- BMC Cancer
- Published
- 2024-01-02
- Volume
- 24
- Issue
- 1
- Pages
- 27-27
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC10763142
- OpenAlex
- W4390510150
- Cited by
- 8
- References
- 33
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Major Research Program of the National Natural Science Foundation of China (91959201)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- gastric cancer, serum metabolomics, tumor recurrence monitoring, biomarkers, lysophosphatidic acid, triglycerides, lysine, sphingosine-1-phosphate, phosphatidylcholine, phosphatidylglycerol, differential metabolites, PLS-DA, hierarchical clustering
- MeSH terms
- Ceramides, Humans, Lysine, Lysophospholipids, Neoplasm Recurrence, Local, Phosphatidylcholines, Phosphatidylglycerols, Sphingosine, Stomach Neoplasms, Triglycerides, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients. https://app.cochat.ai/papers/10.1186/s12885-023-11786-2
- The paper
- Qu, T., Zhang, S., Yang, S., Li, S., & Wang, D. (2024). Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients. BMC Cancer. https://doi.org/10.1186/s12885-023-11786-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.